SIRT7 inhibitor 97491 is a novel SIRT7 inhibitor with antitumor activity. It reduces the deacetylase activity of SIRT7 with an IC50 of 325 nM.

Physicochemical Properties

Molecular Formula	C15H12CLN3O
Molecular Weight	285.728281974792
Exact Mass	285.066
CAS #	1807758-81-1
PubChem CID	146018038
Appearance	Off-white to light yellow solid powder
LogP	3.8
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	3
Heavy Atom Count	20
Complexity	310
Defined Atom Stereocenter Count	0
SMILES	ClC1C=CC(=CC=1)C1=CN=C(NC2C=CC=C(C=2)N)O1
InChi Key	RMRVZWMKRCLSFX-UHFFFAOYSA-N
InChi Code	InChI=1S/C15H12ClN3O/c16-11-6-4-10(5-7-11)14-9-18-15(20-14)19-13-3-1-2-12(17)8-13/h1-9H,17H2,(H,18,19)
Chemical Name	3-N-[5-(4-chlorophenyl)-1,3-oxazol-2-yl]benzene-1,3-diamine
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	SIRT7:325 nM (IC50)
ln Vitro	The SIRT7 inhibitor 97491 (1–10 μM) inhibits MES-SA cell growth without harming HEK293 cells [1].
ln Vivo	Tumor growth in xenograft mice is inhibited by SIRT7 inhibitor 97491 (2 mg/kg; intraperitoneally; for 3 weeks, excluding weekends) [1].
Cell Assay	Cell Proliferation Assay[1] Cell Types: Human uterine sarcoma MES-SA cells Tested Concentrations: 1, 5, 10 μM Incubation Duration: 72 hrs (hours) Experimental Results: Led to more than 50% decrease in cell proliferation at concentrations of 5 and 10 μM. Cell Cytotoxicity Assay[1] Cell Types: Human embryonic kidney cell line HEK293 cells Tested Concentrations: 1, 5, 10 μM Incubation Duration: 24 hrs (hours) Experimental Results: HEK293 cells were almost unaffected.
Animal Protocol	Animal/Disease Models: Balb/c nude mice (18-20 g; 6-8 weeks old) with MES-SA cells[1] Doses: 2 mg/kg Route of Administration: Intraperitoneally injected; for 3 weeks, except on weekends. Experimental Results: Inhibited cancer growth in vivo.
References	[1]. Identification of a Novel SIRT7 Inhibitor as Anticancer Drug Candidate. Biochem Biophys Res Commun. 2019 Jan 8;508(2):451-457.

Solubility Data

Solubility (In Vitro)

DMSO : ~500 mg/mL (~1749.90 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 4.17 mg/mL (14.59 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 2: 10 mg/mL (35.00 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.4998 mL	17.4990 mL	34.9981 mL
	5 mM	0.7000 mL	3.4998 mL	6.9996 mL
	10 mM	0.3500 mL	1.7499 mL	3.4998 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.